Ποια είναι η τιμή για Adagene Inc. (ADAG)

Η τιμή για Adagene Inc. (ADAG) είναι $3.88

Ποια είναι η κεφαλαιοποίηση αγοράς για Adagene Inc. (ADAG)

Η κεφαλαιοποίηση αγοράς για Adagene Inc. (ADAG) είναι $146.08M

Adagene Inc. (ADAG) Τιμή και Κεφαλαιοποίηση Αγοράς

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.

Η τιμή για ADAG	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$136,857 $146.08M	NVDA	$5.152T	+3,527,144.72%
$120,509 $146.08M	AAPL	$4.537T	+3,105,814.12%
$110,723 $146.08M	GOOG	$4.169T	+2,853,581.67%
$96,745.80 $146.08M	MSFT	$3.642T	+2,493,348.47%
$74,496.76 $146.08M	AMZN	$2.805T	+1,919,919.72%

Η τιμή για ADAG

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$136,857 $146.08M